A statement released earlier today by Zacks Investment Research about Evoke Pharma Inc (NASDAQ:EVOK) bumps the target price to $2.50
- Updated: October 8, 2016
Just yesterday Evoke Pharma Inc (NASDAQ:EVOK) traded -1.83% lower at $2.22. Evoke Pharma Inc’s 50-day moving average is $2.03 and its 200-day moving average is $4.26. The last stock price is down -49.55% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 268,375 shares of EVOK traded hands, down from an average trading volume of 1,863,770
Zacks Investment Research bumped up the target of Evoke Pharma Inc (NASDAQ:EVOK) to $2.50 reporting a possible upside of 0.13%.
Previously on 07/19/2016, FBR Capital released a statement about Evoke Pharma Inc (NASDAQ:EVOK) reduced the target price from $17.00 to $9.00. At the time, this indicated a possible upside of 2.64%.
Recent Performance Chart
Evoke Pharma Inc has 52 week low of $1.52 and a 52 week high of $11.11 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 7 brokerages have issued a research note on the company. The average stock price target is $17.68 with 2 brokerages rating the stock a strong buy, 4 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Evoke Pharma Inc (NASDAQ:EVOK)
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.